ARIA

Finding the ‘goldilocks’ zone for Alzheimer’s disease immunotherapies

Development of Appropriate Use Recommendations for lecanemab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

What causes ARIA in response to Alzheimer’s disease immunotherapy?

Lecanemab: a review

Lecanemab vs aducanumab

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease